MetLife (MET) Launches ChatGPT Pet Insurance Plugin, Is The 7% Discount Enough?

MetLife’s AI Pet Insurance Move

MetLife (MET) is pushing deeper into AI-powered distribution by rolling out a ChatGPT plugin that lets pet owners get tailored quotes, complete applications and click through to buy coverage in a single conversational flow.

Against this product launch backdrop, MetLife’s shares trade at US$99.58, with the price drifting slightly lower over the past day and week but posting a 6.65% 90 day share price return and a 23.98% year to date share price gain. The 1 year total shareholder return sits at 30.07% and the 3 year total shareholder return is 86.07%, pointing to momentum that has been building rather than fading, even as recent headlines have focused on incremental updates such as the latest dividend affirmation.

Scan how MetLife’s AI push compares with other insurers tapping automation by reviewing a curated group of list of solid balance sheet and fundamentals (25 results).

MetLife now couples solid recent share gains with a fresh AI push in pet insurance. Does that still leave enough upside in the risk reward for new buyers at roughly US$100 a share?

Most Popular Narrative: 7% Undervalued

MetLife’s most followed valuation story pegs fair value at about $107.38 per share, compared with the latest close at $99.58. This frames the new AI pet insurance push against a view that the stock trades at a discount that is not extreme but still meaningful for long term holders.

Ongoing investment in technology and AI, including more than US$3.2b of spend over five years and visible automation in underwriting, claims and RFP processing, points to further unit cost efficiency that can support net margins and earnings quality.

See why 29 investors see MetLife as 7% undervalued.

Result: Fair Value of $107.38 (UNDERVALUED)

Still, the MetLife story can fray if fee based earnings at MetLife Investment Management stay under pressure or if Retirement and Income Solutions spreads remain weak.

Find out about the key risks to this MetLife narrative.

Another View: MetLife On Earnings Multiples

The story looks different when you move away from fair value models and just look at what investors are paying for MetLife’s earnings today. The stock trades on a P/E of 18.4x, compared with 11x for the broader US insurance group and 14.4x for closer peers.

The fair ratio for MetLife is 13.5x, so the current P/E sits well above both the sector and where the regression work suggests the multiple could drift over time. That gap can be read as investors paying up for quality or as valuation risk if sentiment cools. The key question is which side of that trade you prefer to be on.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages in the MetLife story so far. If you want to move faster than the headlines and build your own stance, start with the full breakdown of 3 key rewards and 1 important warning sign.

Looking For More Investment Ideas Beyond MetLife?

If MetLife has sharpened your focus on quality, do not stop here. Broader idea hunting with structured tools can reveal opportunities you would otherwise miss.

• Target resilient compounders by scanning companies that pair strong finances with steady fundamentals using the 32 resilient stocks with low risk scores.
• Hunt for quality at a discount through the 35 high quality undervalued stocks, which filters for solid businesses priced below their estimated worth.
• Build a cash flow focused watchlist by checking out the 8 dividend fortresses, which highlights higher yielding payouts with an eye on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com